The news is directly about Neurocrine Biosciences. Mizuho's neutral rating suggests that they do not expect the stock to outperform or underperform the market in the near term. However, the increase in price target from $113 to $116 indicates a slightly positive outlook, but it's not significant enough to suggest a strong upward movement in the short term.